| |
|
|
|
|
|
 |
| |
|
³×¿À½º¹ÎÁÖ»ç(¸ÞĥȲ»ê³×¿À½ºÆ¼±×¹Î) [Neostigmine Methylsulfate]
|
Àü¹®ÀǾàǰ | »èÁ¦ | ºÐ¾÷¿¹¿ÜÀǾàǰ(52)
|
|
¼öÀÔÀǾàǰ
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
657800040[A20450381]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ml/¾ÚÇÃ(2007.03.01)(ÇöÀç¾à°¡)
\300 ¿ø/1ml/¾ÚÇÃ(2003.10.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹«»öÅõ¸íÇÑ ¾×ü°¡ µç °¥»öÅõ¸íÇÑ ¾ÚÇ® ÁÖ»çÁ¦ÀÌ´Ù [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
1¹Ð¸®¸®ÅÍ ¡¿ 10, 30, 50 ¾ÚÇà |
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
1. ÁßÁõ ±Ù¹«·ÂÁõ
2. ºñÅ»ºÐ±Ø¼º ±ÙÀÌ¿ÏÁ¦(Åõº¸Äí¶ó¸° µî)ÀÇ ÇØµ¶Á¦
3. ¼ö¼úÈÄ․ºÐ¸¸ÈÄ ¹è´¢°ï¶õ
|
| 1ÀÏ ÃÖ´ë Åõ¿©·® |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ : ³×¿À½ºÆ¼±×¹Î¸ÞƿȲ»ê¿°À¸·Î¼ 1ȸ 0.25¢¦0.5§· 1ÀÏ 1¢¦3ȸ ±ÙÀ° ¶Ç´Â ÇÇÇÏÁÖ»çÇÑ´Ù. 1ÀÏ 5§·À» ÃʰúÇÏÁö ¾Ê´Â´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
1) ¼Òȱ⠶Ǵ ¿ä·ÎÀÇ ±âÁúÀû Æó»ö ȯÀÚ
2) ÀÌ ¾à¿¡ °ú¹ÎÁõ ȯÀÚ
3) ¹ÌÁֽŰæ±äÀåÁõ ȯÀÚ
4) Å»ºÐ±Ø¼º±ÙÀÌ¿ÏÁ¦(¼®»ç¸ÞÅä´½) Åõ¿©ÁßÀΠȯÀÚ
5) ½Å»ý¾Æ, ¹Ì¼÷¾Æ (º¥Áú¾ËÄÚ¿ÃÀ» ÇÔÀ¯Çϰí ÀÖ´Ù.)
|
| ½ÅÁßÅõ¿© |
1) ±â°üÁöõ½Ä ȯÀÚ
2) °©»ó¼±±â´ÉÇ×ÁøÁõ ȯÀÚ
3) °ü»óµ¿¸ÆÆó»ö ȯÀÚ
4) ¼¸Æ ȯÀÚ
5) ¼Òȼº±Ë¾ç ȯÀÚ
6) °£Áú ȯÀÚ
7) ÆÄŲ½¼ÁõÈıº ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
1) Äݸ°¼º ¹ßÁõ(cholinergic crisis) : Äݸ°¼º ¹ßÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î º¹Åë, ¼³»ç, ¹ßÇÑ, Ÿ¾×ºÐºñ°ú´Ù, Ãൿ, ¼±À¯¼Ó¿¬Ãà µîÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â ¿¡µå·ÎÆ÷´½¿°È¹°À» Åõ¿©Çϰí, Áõ»óÀÌ ¾ÇÈ ¶Ç´Â ºÒº¯ÇÏ´Â °æ¿ì´Â Áï½Ã ÁßÁöÇÏ°í ¾ÆÆ®·ÎÇÉȲ»ê¿° 0.5¢¦1§·À» Á¤¸ÆÁÖ»çÇÑ´Ù. Çʿ信 µû¶ó ÀΰøÈ£Èí ¶Ç´Â ±â°üÀý°³ µîÀ» ÇÏ¿© ±âµµ¸¦ È®º¸ÇÑ´Ù.
2) ¼øÈ¯±â°è : ¶§¶§·Î Ç÷¾Ð°ÇÏ, ¼¸Æ, ºó¸ÆÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) È£Èí±â°è : ¶§¶§·Î ±â°üÁö°æ·Ã, ±âµµºÐºñÇ×ÁøÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) ¼Òȱâ°è : º¹Åë, ¶§¶§·Î Ÿ¾×ºÐºñ°ú´Ù, ±¸¿ª・±¸Åä, ¼³»ç°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) Á¤½Å½Å°æ°è : ¶§¶§·Î ¹ßÇÑ, ¾îÁö·¯¿ò, ´ë·®Åõ¿©¿¡ ÀÇÇÏ¿© ¶§¶§·Î ºÒ¾È, ÈïºÐ, ÇãÅ», ¹«·Â, ±Ù¿¬Ãà, °ñ°Ý±ÙÀÇ ¼¶À¯¼Ó¿¬ÃàÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
6) °ú¹ÎÁõ : °ú¹ÎÁõÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
7) ±âŸ : ¶§¶§·Î ÃൿÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) Å»ºÐ±Ø¼º±ÙÀÌ¿ÏÁ¦(¼®»ç¸ÞÅä´½)¿Í º´¿ëÇÏ´Â °æ¿ì¿¡ Å»ºÐ±Ø¼º±ÙÀÌ¿ÏÁ¦ÀÇ ÀÛ¿ëÀ» Áõ°½Ãų ¼ö ÀÖÀ¸¹Ç·Î º´¿ëÇÏÁö ¾Ê´Â´Ù.
2) Äݸ°È¿´É¾à(¾Æ¼¼Æ¿Äݸ° µî)°ú º´¿ëÇÏ´Â °æ¿ì¿¡ »óÈ£ÀÇ ÀÛ¿ëÀÌ Áõ°µÇ¹Ç·Î º´¿ë½Ã ÁÖÀÇÇÑ´Ù.
3) ºÎ±³°¨½Å°æ¾ïÁ¦Á¦´Â Äݸ°¼º ¹ßÁõÀÇ Ãʱâ Áõ»óÀ» ÀºÆó½ÃÄÑ ÀÌ ¾àÀÇ °úÀ×Åõ¿©¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ ¾àÀ» Åõ¿©ÇÏ´Â °æ¿ì¿¡ ºÎ±³°¨½Å°æ¾ïÁ¦Á¦ÀÇ »ó¿ëÀ» ÇÇÇÑ´Ù. |
| Off-label Usage |
[Á¶È¸]
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
657800040[A20450381]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ml/¾ÚÇÃ(2007.03.01)(Ãֽžడ)
\300 ¿ø/1ml/¾ÚÇÃ(2003.10.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁý ´Ù¿î·Îµå]
|
| Á¦Ç°¼º»ó |
¹«»öÅõ¸íÇÑ ¾×ü°¡ µç °¥»öÅõ¸íÇÑ ¾ÚÇ® ÁÖ»çÁ¦ÀÌ´Ù
[Á¦ÇüÁ¤º¸ È®ÀÎ]
|
| Æ÷À塤À¯Åë´ÜÀ§ |
1¹Ð¸®¸®ÅÍ ¡¿ 10, 30, 50 ¾ÚÇà |
| º¸°ü¹æ¹ý |
Â÷±¤º¸°ü, ¹ÐºÀ¿ë±â |
µ¿ÀÏÁÖ¼ººÐÄÚµå °Ë»ö¼øÀ§ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
Ư¼ö°ü¸®ÀǾàǰ ºÎ°¡Á¤º¸ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Neostigmine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Neostigmine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. By interfering with the breakdown of acetylcholine, neostigmine indirectly stimulates both nicotinic and muscarinic receptors. It does not cross the blood-brain barrier.
|
| Pharmacology |
Neostigmine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
|
| Metabolism |
Neostigmine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cholinesterase
|
| Protein Binding |
Neostigmine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Protein binding to human serum albumin ranges from 15 to 25 percent.
|
| Half-life |
Neostigmine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ The half-life ranged from 42 to 60 minutes with a mean half-life of 52 minutes.
|
| Absorption |
Neostigmine¿¡ ´ëÇÑ Absorption Á¤º¸ Neostigmine bromide is poorly absorbed from the gastrointestinal tract following oral administration
|
| Pharmacokinetics |
Neostigmine MethylsulfateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ :
- °æ±¸ : 45-75ºÐ
- ±ÙÀ°ÁÖ»ç : 20-30ºÐ
- Á¤¸ÆÁÖ»ç : 4-8ºÐ
- ÀÛ¿ëÁö¼Ó½Ã°£ : °æ±¸, ±ÙÀ°ÁÖ»ç, Á¤¸ÆÁÖ»ç : 2-4 ½Ã°£
- Èí¼ö : °æ±¸ : Àß Èí¼öµÇÁö ¾ÊÀ½ (2% À̳»)
- ´Ü¹é°áÇÕ : 15-25%
- ´ë»ç : Cholinesterase¿¡ ÀÇÇØ °¡¼öºÐÇØ, °£¿¡¼ ´ë»çµÊ
- ¹Ý°¨±â : Á¤»ó ½Å±â´É : 0.5-2.1 ½Ã°£ (¸»±â½ÅÁúȯ¿¡¼´Â ¿¬ÀåµÊ)
- ¼Ò½Ç : 24½Ã°£ À̳»¿¡´Â 80%°¡ ½Å¹è¼³µÊ (¾à 50%´Â ¹Ìº¯Èü·Î, 30%´Â ´ë»çü·Î)
|
| Biotransformation |
Neostigmine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Neostigmine undergoes hydrolysis by cholinesterase and is also metabolized by microsomal enzymes in the liver.
|
| Toxicity |
Neostigmine¿¡ ´ëÇÑ Toxicity Á¤º¸ Overdosage of Neostigmine can cause cholinergic crisis, which is characterized by increasing muscle weakness, and through involvement of the muscles of respiration, may result in death. The LD 50 of neostigmine methylsulfate in mice is 0.3 ¡¾ 0.02 mg/kg intravenously, 0.54 ¡¾ 0.03 mg/kg subcutaneously, and 0.395 ¡¾ 0.025 mg/kg intramuscularly; in rats the LD 50 is 0.315 ¡¾ 0.019 mg/kg intravenously, 0.445 ¡¾ 0.032 mg/kg subcutaneously, and 0.423 ¡¾ 0.032 mg/kg intramuscularly.
|
| Drug Interactions |
Neostigmine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Neostigmine¿¡ ´ëÇÑ Description Á¤º¸ A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. [PubChem]
|
| Drug Category |
Neostigmine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Cholinesterase InhibitorsParasympathomimetics
|
| Smiles String Canonical |
Neostigmine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C
|
| Smiles String Isomeric |
Neostigmine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN(C)C(=O)OC1=CC(=CC=C1)[N+](C)(C)C
|
| InChI Identifier |
Neostigmine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1
|
| Chemical IUPAC Name |
Neostigmine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ [3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-07-25
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|